No significant interaction effects seen between genetic predisposition and sweetener intake for central precocious puberty risk
TUESDAY, July 15, 2025 (HealthDay News) — Sweetener consumption and genetic predisposition are independently associated with the risk for central precocious puberty (CPP), according to a study presented at ENDO 2025, the annual meeting of the Endocrine Society, held from July 12 to 15 in San Francisco.
Yang-Ching Chen, M.D., Ph.D., from the Taipei Municipal Wan Fang Hospital in Taiwan, examined sweetener consumption, genetic predisposition, and CPP risk interactions in a population-based cohort of 1,407 children to inform prevention strategies. Validated questionnaires and urinary biomarkers were used to assess sweetener intake, and genetic predisposition was quantified using polygenic risk scores derived from 19 CPP-related single nucleotide polymorphisms.
Chen found that 481 participants were diagnosed with CPP. Significant associations were seen for aspartame, sucralose, glycyrrhizin, and added sugars with an increased risk for CPP, especially in genetically predisposed individuals. There was a dose-dependent relationship noted, with CPP risk amplified by higher intake of these sweeteners. In boys, sucralose showed a stronger association with CPP, while glycyrrhizin, sucralose, and added sugars were especially impactful in girls. There were no significant interaction effects noted between genetic predisposition and sweetener intake.
“The findings are directly relevant to families, pediatricians, and public health authorities,” Chen said in a statement. “They suggest that screening for genetic risk and moderating sweetener intake could help prevent early puberty and its long-term health consequences.”
Sugar Exposure in Early Life Linked to Anxiety in Adulthood
Gene Mutation Identified That Increases Lung Cancer Risk
Genetics, Diabetes Tied to MASLD-Associated Cirrhosis Before Age 50
Family History of CRC Increases CRC Risk Similarly in IBD, General Population
Personalized Support Boosts Families" Genetic Testing for Hereditary Cancers
Serum 25(OH)D May Serve as Biomarker of Disease Activity in IBD
Surveillance Colonoscopy at Five Years After Adenoma Removal Noninferior to Three Years
Relapse Rare After Appendiceal Adenocarcinoma Resection